Replies to post #902 on Fate Therapeutics Inc (FATE)

[NY1972]

what do you mean by T cell enhancer?
mica/b trunk targeting makes 836 only in class even if other ipsc derived CART catch up.

[NY1972]

I think long term CART persistence is a myth. Cancers evolve to survive from CART killing. The roles of 836 + cetuximab are:
1. 400 MG cetuximab primes TME
2. 2 doses 836 deplete terminal exhausted T cells, cancer clones with high shedding
3. cetuximab/ endogenous NK ADCC for long term OS/PFS

use LD taxol for MSS CRC with low egfr

[NY1972]

Does 836 deplete immune cells with intermediate 4-1BB expression? It should delete Treg in MSS stage 4 CRC. What about the other activated T cells?

[KIPK]

jonfoeuk - LOL...

T-Cell enhancers////